• Simris Group reported Q2 net revenue down 71% to SEK 196,000 versus the year-earlier quarter.
• EBITDA loss narrowed 35% to SEK 1.93 million; operating loss improved 19% to SEK 5.44 million.
• First-half net revenue fell 27% to SEK 620,000; EBITDA loss narrowed 39% to SEK 4.11 million.
• Operating loss improved 21% to SEK 11.06 million; divestment talks advanced for Hammenhög assets with a second prospective buyer.
• Post-quarter, warrant holders signaled exercises totaling EUR 1 million; Andreas Pahl named CEO of Simris Biologics, Tiffany J. Vora appointed adviser.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simris Group AB published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.